$184 Million is the total value of Alerce Investment Management, L.P.'s 7 reported holdings in Q2 2021. The portfolio turnover from Q1 2021 to Q2 2021 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| AMWL | AMERICAN WELL CORPcl a | $79,264,000 | -27.6% | 6,300,773 | 0.0% | 43.02% | -11.1% | |
| ANNX | ANNEXON INC | $44,007,000 | -19.1% | 1,954,978 | 0.0% | 23.89% | -0.8% | |
| ALRN | AILERON THERAPEUTICS INC | $20,762,000 | -12.6% | 16,609,449 | 0.0% | 11.27% | +7.2% | |
| AKBA | AKEBIA THERAPEUTICS INC | $17,633,000 | +12.0% | 4,652,561 | 0.0% | 9.57% | +37.4% | |
| ARPO | AERPIO PHARMACEUTICALS INC | $9,501,000 | +31.0% | 5,621,835 | 0.0% | 5.16% | +60.7% | |
| ASMB | ASSEMBLY BIOSCIENCES INC | $8,643,000 | -15.7% | 2,227,500 | 0.0% | 4.69% | +3.5% | |
| GBT | GLOBAL BLOOD THERAPEUTICS IN | $4,422,000 | -14.1% | 126,270 | 0.0% | 2.40% | +5.4% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-08-11
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| AMERICAN WELL CORP | 12 | Q3 2023 | 62.9% |
| ANNEXON INC | 12 | Q3 2023 | 35.9% |
| AKEBIA THERAPEUTICS INC | 12 | Q3 2023 | 31.6% |
| ASSEMBLY BIOSCIENCES INC | 12 | Q3 2023 | 8.7% |
| AADI BIOSCIENCES INC | 9 | Q3 2023 | 24.1% |
| AILERON THERAPEUTICS INC | 8 | Q3 2022 | 14.4% |
| GLOBAL BLOOD THERAPEUTICS IN | 8 | Q3 2022 | 23.4% |
| AILERON THERAPEUTICS INC | 4 | Q3 2023 | 2.3% |
| AERPIO PHARMACEUTICALS INC | 3 | Q2 2021 | 5.2% |
View Alerce Investment Management, L.P.'s complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-09 |
| 13F-HR | 2023-11-13 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-04 |
| 13F-HR | 2022-05-13 |
| 13F-HR | 2022-02-09 |
| 13F-HR | 2021-11-15 |
View Alerce Investment Management, L.P.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.